TIRIBELLI, MARIO
 Distribuzione geografica
Continente #
NA - Nord America 118
EU - Europa 90
AS - Asia 82
SA - Sud America 1
Totale 291
Nazione #
US - Stati Uniti d'America 117
SG - Singapore 72
IT - Italia 57
IE - Irlanda 8
BG - Bulgaria 5
RU - Federazione Russa 4
VN - Vietnam 4
CH - Svizzera 3
DE - Germania 3
IN - India 3
AT - Austria 2
BE - Belgio 2
CN - Cina 2
NL - Olanda 2
BR - Brasile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
JM - Giamaica 1
LT - Lituania 1
PK - Pakistan 1
PL - Polonia 1
Totale 291
Città #
Singapore 59
Santa Clara 55
Ashburn 8
Dublin 8
Boardman 7
Milan 7
Sofia 5
Capaci 4
Vicenza 3
Bengaluru 2
Bologna 2
Brussels 2
Collecchio 2
Ho Chi Minh City 2
Lancenigo-Villorba 2
Lonato 2
Montemiletto 2
Moscow 2
New York 2
Pescia 2
Porto Torres 2
Rome 2
Verona 2
Wayne 2
Athens 1
Baggiovara 1
Catania 1
Cesena 1
Dübendorf 1
Faisalabad 1
Fiesole 1
Frankfurt am Main 1
Lausanne 1
Montecatini Terme 1
Munich 1
Nuremberg 1
Pardubice 1
Petriolo 1
Pune 1
São Paulo 1
Trieste 1
Warsaw 1
Totale 204
Nome #
Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience 26
Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study 23
Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial 22
Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A ``Campus CML{''} Study 17
Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study 17
Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients 17
Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib 15
Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome 14
First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria 14
Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence 12
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 12
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 12
Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study 12
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. ACampus CMLstudy 11
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 11
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 10
Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group 10
Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study 10
One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience 9
Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission 8
Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis 8
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 8
The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients 7
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 6
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 4
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series 3
Totale 318
Categoria #
all - tutte 2.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.784


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024167 32 13 15 25 17 8 6 5 0 21 9 16
2024/2025151 5 27 17 17 70 15 0 0 0 0 0 0
Totale 318